Kristin Moore, MD
Allergy & Immunology · Houston, TXNPI 1447257530
Payments from drug & device makers
Across 754 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- CSL Behring$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Sanofi$1K
- Grifols USA, LLC$861
- plus $5K from 27 others
What the payments were for
- Consulting fees$230%
- Food & beverage$15,117100%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 147 | $3,285 |
| GSK | 127 | $1,772 |
| CSL Behring | 72 | $1,548 |
| Takeda Pharmaceuticals U.S.A., Inc. | 67 | $1,534 |
| Sanofi | 50 | $1,186 |
| Grifols USA, LLC | 45 | $861 |
| Biocryst US Sales Co., LLC | 32 | $557 |
| Regeneron Healthcare Solutions, Inc. | 25 | $511 |
| Novartis | 23 | $467 |
| Optinose US, Inc. | 23 | $461 |
| Amgen | 20 | $446 |
| Kaleo, Inc. | 19 | $349 |
| Pharming Healthcare, Inc. | 16 | $342 |
| Pfizer | 19 | $333 |
| Shire North American Group Inc | 15 | $285 |
| Blueprint Medicines Corporation | 5 | $229 |
| Incyte Corporation | 5 | $212 |
| Genentech USA, Inc. | 7 | $132 |
| Octapharma USA, Inc. | 4 | $120 |
| Teva Pharmaceuticals USA, Inc. | 7 | $101 |
| LEO Pharma Inc. | 5 | $95 |
| Boehringer Ingelheim | 5 | $89 |
| Mylan Specialty L.p. | 3 | $47 |
| Stryker | 2 | $28 |
| Apria Healthcare LLC | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 3 | $24 |
| ADMA Biomanufacturing LLC | 1 | $23 |
| Biocryst Pharmaceuticals, Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Alk-abello, Inc | 1 | $20 |
| Medtronic | 1 | $16 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,175 in reported general payments places this provider in the 70th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 12 | $608,217 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 12 | $209,275 |
| Dupixent PenDupilumab | 29 | $152,850 |
| Dupixent SyringeDupilumab | 23 | $113,856 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $105,059 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $76,550 |
| NucalaMepolizumab | 12 | $45,147 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $44,415 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $33,718 |
| SymbicortBudesonide/Formoterol Fumarate | 67 | $22,584 |
| Spiriva RespimatTiotropium Bromide | 18 | $15,169 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $14,058 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $13,773 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 59 | $11,645 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 64 | $9,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Cuvitru | $1,534 | $713,27623 claims |
| PfizerPanzyga | $333 | $209,27512 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $1,772 | $103,33596 claims |
| Grifols USA, LLCGamunex-C | $861 | $76,55013 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,285 | $56,302107 claims |
| Boehringer IngelheimSpiriva Respimat | $89 | $15,16918 claims |
| Hikma Pharmaceuticals USAEpinephrine | $20 | $8,63147 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $101 | $1,73311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Houston
- Sara AnvariHouston$181K
- Joud HajjarHouston$176K
- Juan ZambranoHouston$146K
- Mahboobeh MahdaviniaHouston$78K
- Ekta PereraHouston$75K
- Julie PatelHouston$42K
- Sarah NicholasHouston$32K
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
- Barbara BaxterDallas$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.